Revive Therapeutics Ltd
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious dise… Read more
Market Cap & Net Worth: Revive Therapeutics Ltd (RVVTF)
Revive Therapeutics Ltd (OTCQB:RVVTF) has a market capitalization of $5.78 Million ($5.78 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #30807 globally and #10149 in its home market, demonstrating a 97.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Revive Therapeutics Ltd's stock price $0.01 by its total outstanding shares 418564000 (418.56 Million).
Revive Therapeutics Ltd Market Cap History: 2017 to 2025
Revive Therapeutics Ltd's market capitalization history from 2017 to 2025. Data shows change from $142.31 Million to $5.78 Million (-20.75% CAGR).
Revive Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Revive Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RVVTF by Market Capitalization
Companies near Revive Therapeutics Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Revive Therapeutics Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Revive Therapeutics Ltd Historical Marketcap From 2017 to 2025
Between 2017 and today, Revive Therapeutics Ltd's market cap moved from $142.31 Million to $ 5.78 Million, with a yearly change of -20.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.78 Million | +53.33% |
| 2024 | $3.77 Million | -59.09% |
| 2023 | $9.21 Million | -73.81% |
| 2022 | $35.16 Million | -68.66% |
| 2021 | $112.18 Million | -44.74% |
| 2020 | $203.00 Million | +1103.47% |
| 2019 | $16.87 Million | -43.79% |
| 2018 | $30.01 Million | -78.91% |
| 2017 | $142.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Revive Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.78 Million USD |
| MoneyControl | $5.78 Million USD |
| MarketWatch | $5.78 Million USD |
| marketcap.company | $5.78 Million USD |
| Reuters | $5.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.